Yongjin Gong

Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models

Francois Gonzalvez, Xiaotian Zhu, Wei‐Sheng Huang et al. · Cancer Research · 2016 · 29 citations

Medicine, Oncology, Pharmacology +17

Intestinally Targeted Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitors Robustly Suppress Postprandial Triglycerides

Michael H. Serrano‐Wu, Gary M. Coppola, Yongjin Gong et al. · ACS Medicinal Chemistry Letters · 2012 · 27 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non–small cell lung cancer

Wei‐Sheng Huang, Feng Li, Yongjin Gong et al. · Bioorganic & Medicinal Chemistry Letters · 2022 · 25 citations · Full text

Medicine, Oncology, Pharmacology +13

Discovery of an Orally Bioavailable Benzimidazole Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor That Suppresses Body Weight Gain in Diet-Induced Obese Dogs and Postprandial Triglycerides in Humans

Katsumasa Nakajima, Ricardo E. Chatelain, Kevin B. Clairmont et al. · Journal of Medicinal Chemistry · 2017 · 18 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17